KAT8-catalyzed lactylation promotes eEF1A2-mediated protein synthesis and colorectal carcinogenesis

Bingteng Xie(Beijing Institute of Technology), Mengdi Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jie Li(Peking University), Jianxin Cui(Chinese People's Liberation Army), Pengju Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Fangming Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxi Wu(University of Virginia), Wei‐Wei Deng(Chinese Academy of Medical Sciences & Peking Union Medical College), Jihong Ma(Peking University), Xinyu Li(Peking University), Bingchen Pan(Beijing Institute of Technology), Baohui Zhang(China Medical University), Hongbing Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Aiqin Luo(Beijing Institute of Technology), Yinzhe Xu(People's Liberation Army No. 150 Hospital), Mo Li(Peking University), Yang Pu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Proceedings of the National Academy of Sciences
February 15, 2024
Cited by 210Open Access
Full Text

Abstract

Aberrant lysine lactylation (Kla) is associated with various diseases which are caused by excessive glycolysis metabolism. However, the regulatory molecules and downstream protein targets of Kla remain largely unclear. Here, we observed a global Kla abundance profile in colorectal cancer (CRC) that negatively correlates with prognosis. Among lactylated proteins detected in CRC, lactylation of eEF1A2K408 resulted in boosted translation elongation and enhanced protein synthesis which contributed to tumorigenesis. By screening eEF1A2 interacting proteins, we identified that KAT8, a lysine acetyltransferase that acted as a pan-Kla writer, was responsible for installing Kla on many protein substrates involving in diverse biological processes. Deletion of KAT8 inhibited CRC tumor growth, especially in a high-lactic tumor microenvironment. Therefore, the KAT8-eEF1A2 Kla axis is utilized to meet increased translational requirements for oncogenic adaptation. As a lactyltransferase, KAT8 may represent a potential therapeutic target for CRC.


Related Papers